Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an update.
Roquefort Therapeutics PLC announced its audited results for the year ending December 31, 2024, highlighting significant corporate activities and strategic progress. The company signed agreements for the sale of its subsidiaries, Lyramid Pty Ltd and Oncogeni Ltd, for a combined total of over $20 million, aiming to generate short-term value and pursue new opportunities. Additionally, Roquefort implemented cost-cutting measures, restructured its board, and raised funds through convertible loan notes and private placements to support its operations and strategic goals. The company continued its pre-clinical development programs, reporting positive results in its Midkine mRNA and STAT-6 siRNA therapeutics, positioning itself for future growth in the oncology market.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on developing first-in-class medicines in the high-value and high-growth immunology and oncology markets. The company’s portfolio includes novel patent-protected pre-clinical anti-cancer medicines, such as Midkine mRNA therapeutics and STAT-6 siRNA therapeutics, targeting solid tumors and offering potential first-in-class treatments.
YTD Price Performance: -54.32%
Average Trading Volume: 3,052,862
Technical Sentiment Signal: Buy
Current Market Cap: £2.87M
See more insights into ROQ stock on TipRanks’ Stock Analysis page.